Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...

The aetiology of T1D is largely unknown, but it is thought that a genetic predisposition, environmental factors and distinctive metabolic changes are involved in the initiation, development and ...

Empagliflozin vs placebo was associated with greater reductions in risk for cardiovascular disease among patients with type 1 diabetes. Sodium–glucose cotransporter inhibitors (SGLTis) are ...

We are just about a month away from a classic Capital Region Walk -- the Breakthrough T1D walk in Clifton Park. Breakthrough T1D is the leading Type 1 Diabetes research and advocacy organization ...

People with LADA follow similar T1D practices with insulin, eating, exercise, and blood sugar management. Type 1.5 diabetes is commonly known as LADA, or latent autoimmune diabetes in adults.

Islet transplantation offered significant benefits in reducing mortality and other complications in patients with type 1 diabetes (T1D) over a median follow-up duration exceeding 10 years.